Monitor for insider or institutional selling activity in the near term, as the shelf effectiveness enables immediate resale. Any warrant exercises would be accretive to cash but dilutive to shares outstanding — track filings for exercise patterns. The neutral sentiment reflects lack of immediate company proceeds but ongoing capital market access.
Price Chart
Executive Summary
Tempest Therapeutics' S-3 shelf registration (File No. 333-294740) became effective on April 3, 2026, allowing selling stockholders to immediately resell up to 2,777,781 shares of common stock. The company will not receive proceeds from these sales, but may receive up to $4 million if warrants are exercised. This follows recent clinical progress and a strategic acquisition, suggesting opportunistic capital flexibility rather than distress.
Key Facts
- S-3 shelf registration (333-294740) became effective on April 3, 2026
- Registration covers resale of 2,777,781 shares by selling stockholders
- Shares include those issued in a recent private placement and upon warrant exercise
- Company will not receive proceeds from resale, but may receive up to $4 million from warrant exercises
- Follows strong clinical data and strategic acquisition, indicating proactive capital structure management
Financial Impact
Potential $4 million in future proceeds if all warrants are exercised; no immediate dilution from resale
Risk Factors
- Potential overhang from immediate resale of 2.8M shares by selling stockholders
- Future dilution if warrants are exercised, though proceeds would support operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001088 |
| Document: 9999999995-26-001088-index.html | 9999999995-26-001088 |
| Document: 9999999995-26-001088.txt | 9999999995-26-001088 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | DEF 14A | $0.5102 | awaiting T+20 | awaiting T+20 | $0.5110 (−0.16%) |
Oct 20, 2026 7d ago | DEFA14A | $0.5282 | awaiting T+20 | awaiting T+20 | $0.5110 (−3.26%) |
Oct 20, 2026 7d ago | 8-K | $0.5282 | awaiting T+20 | awaiting T+20 | $0.5110 (−3.26%) |
Oct 19, 2026 8d ago | 8-K | $0.5762 | awaiting T+20 | awaiting T+20 | $0.5110 (−11.32%) |
Oct 2, 2026 26d ago | EFFECT | $0.8112 | awaiting T+20 | awaiting T+20 | $0.5110 (+37.01%) |
Sep 25, 2026 4w ago | S-3 | $0.8316 $0.5102 | ▲ +38.65% | ▲ +38.62% | $0.5110 (+38.55%) |
Sep 17, 2026 5w ago | 8-K | $0.9680 $0.6240 | ▼ −35.54% | ▼ −35.74% | $0.5110 (−47.21%) |
Sep 16, 2026 5w ago | DEFA14A | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5110 (−42.91%) |
Sep 16, 2026 5w ago | 8-K | $0.8950 $0.6350 | ▼ −29.05% | ▼ −30.51% | $0.5110 (−42.91%) |
Sep 11, 2026 6w ago | Press Release | $0.8117 $0.7601 | ▲ +6.36% | ▲ +8.23% | $0.5110 (+37.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers